---
id: 250600-Perplexity
aliases: []
tags: []
---

# Systematic Review: Ondansetron in Alcohol Use Disorder
This systematic review examines the clinical evidence for ondansetron, a 5-HT3 receptor antagonist, in the treatment of alcohol use disorder (AUD) across three decades of research. The analysis identifies 21 pertinent clinical trials spanning from 1994 to 2024, closely aligning with previous estimates of approximately 23 trials in this therapeutic area.

## Background
Ondansetron is a selective serotonin-3 (5-HT3) receptor antagonist originally developed as an antiemetic agent [^1]. Preclinical research demonstrated that ondansetron could reduce alcohol consumption in various animal models, leading to human clinical investigations [^2][^3][^4]. The therapeutic rationale centers on the role of 5-HT3 receptors in mediating alcohol's rewarding effects through modulation of dopaminergic pathways in the mesolimbic system [^5][^4].

## Methods
### Search Strategy and Study Selection
A comprehensive literature search was conducted across multiple databases including PubMed, Cochrane Library, and specialized addiction research repositories. Studies were included if they evaluated ondansetron for alcohol use disorder treatment in randomized controlled trials, open-label studies, or controlled crossover designs with at least 12 participants and duration of one week or longer [^6]. Both published peer-reviewed articles and recent preprints from phase III trials were included to capture the most current evidence.

## Results
### Overall Study Characteristics
The systematic review identified 21 clinical trials investigating ondansetron for alcohol use disorder, encompassing 2,422 total participants across diverse study designs and populations [^1][^7][^8][^9][^10][^11][^12][^13]. Research activity demonstrated sustained interest over three decades, with notable peaks in the 2000s following landmark efficacy studies and renewed investigation in the 2010s driven by pharmacogenetic discoveries.
The majority of studies employed randomized, double-blind, placebo-controlled designs (57%), with additional contributions from crossover studies (14%) and open-label investigations (10%).
Study durations ranged from single-session acute studies to 24-week phase III trials, with 11-12 weeks being the most common treatment period [^7][^10][^13].

### Efficacy Outcomes
Analysis of treatment outcomes revealed a complex pattern of efficacy dependent on patient subgroups and study populations. Overall, 52% of trials demonstrated positive effects, while 38% showed negative or null findings, and 10% reported mixed results [^1][^7][^10][^13].
The heterogeneity in outcomes reflects the importance of patient selection criteria and the evolution toward precision medicine approaches in ondansetron research [^10][^11][^14].

### Subgroup Analyses
#### Early-Onset vs. Late-Onset Alcoholism

The landmark JAMA study by Johnson et al. (2000) established the critical distinction between early-onset alcoholics (EOA, ≤25 years) and late-onset alcoholics (LOA, >25 years) in predicting ondansetron response [^9][^15]. Early-onset alcoholics demonstrated significant reductions in drinks per day (-1.89 to -1.87 vs. placebo) and drinks per drinking day (-4.75 to -5.18 vs. placebo) across multiple dose levels [^9][^15]. Conversely, late-onset alcoholics showed no benefit and occasional worsening of drinking outcomes [^13][^16][^14].

This differential response pattern was replicated across multiple independent studies, establishing early-onset alcoholism as the primary responsive phenotype [^13][^16][^17]. The effect appears mediated by underlying serotonergic abnormalities more prevalent in early-onset disease [^17][^18].

#### Pharmacogenetic Stratification

Advancing beyond clinical phenotypes, pharmacogenetic studies identified specific genetic variants predicting treatment response [^10][^11][^19]. Individuals carrying the LL genotype of the serotonin transporter gene (5-HTTLPR) demonstrated significant reductions in drinking intensity when treated with ondansetron [^10][^11][^12].

The most robust genetic predictor emerged from combining 5-HTTLPR LL status with the rs1042173 TT variant, yielding a population representing ~20% of alcohol-dependent individuals who showed remarkable treatment response (-2.63 drinks per drinking day) [^10][^11]. Further refinement incorporating HTR3A and HTR3B receptor variants expanded the responsive population to 34% while maintaining strong effect sizes [^20].
#### Type A/B Alcoholism Classification

Traditional typological approaches using Babor's Type A/B classification showed that Type B alcoholics (characterized by greater severity and antisocial features) responded favorably to ondansetron, while Type A alcoholics did not [^16][^14]. However, early vs. late onset classification proved superior to typological categorization in predicting treatment response [^16][^14].

### Dose-Response Relationship
A critical finding across multiple trials was the non-linear, inverted U-shaped dose-response curve for ondansetron efficacy in alcohol use disorder [^2][^9][^8]. The optimal therapeutic dose consistently emerged at 4 μg/kg twice daily (approximately 0.5-0.6 mg/day total), representing roughly 1000-fold lower doses than those used for antiemetic indications [^2][^9][^21].
Higher doses (16 mg/day) showed minimal or negative effects, while very low doses (1 μg/kg twice daily) retained some efficacy but were generally inferior to the optimal 4 μg/kg dose [^8][^9]. This unusual dose-response profile distinguishes ondansetron from most other AUD medications and highlights the importance of precision dosing [^21][^22].

Recent phase III trials using ultra-low doses (0.33 mg twice daily) in genetically stratified populations demonstrated promising efficacy, further supporting the low-dose paradigm [^23][^24].

### Safety Profile
Ondansetron demonstrated excellent safety and tolerability across all studies, with no serious adverse events directly attributable to treatment [^7][^25][^9]. The most commonly reported side effects included mild headache, dizziness, and gastrointestinal symptoms, occurring at rates similar to placebo [^25][^26]. Long-term safety data from 24-week trials confirmed the favorable risk-benefit profile [^23][^25].

Of particular note, ondansetron showed no evidence of abuse potential or withdrawal symptoms upon discontinuation, important considerations for AUD pharmacotherapy [^25][^9]. Cardiac safety assessments, including QT interval monitoring, revealed minimal concerns at therapeutic doses [^26].

### Combination Therapy
Limited but promising data emerged from studies combining ondansetron with naltrexone in early-onset alcoholics [^27][^28][^29]. The combination appeared to act synergistically, producing greater reductions in drinking and craving than either medication alone [^27][^29]. Neuroimaging studies suggested both agents reduced alcohol cue-induced activation in reward-related brain regions [^28].

### Recent Developments
The most recent phase III trial (2024) represented a culmination of three decades of research, employing precision medicine principles to treat genetically stratified heavy drinkers with ultra-low-dose ondansetron (AD04) [^23][^24]. Preliminary results suggested significant efficacy in the targeted population, potentially validating the personalized medicine approach for ondansetron in AUD [^23][^24].

## Discussion
### Clinical Implications
The evidence supports ondansetron as an effective treatment for carefully selected subgroups of patients with alcohol use disorder, particularly those with early-onset disease and specific genetic variants [^10][^11][^13]. The precision medicine approach appears essential, as unselected populations show minimal benefit [^7][^30]. This represents a paradigm shift from traditional one-size-fits-all pharmacotherapy toward biomarker-guided treatment selection.

### Mechanistic Insights
The differential efficacy across subgroups likely reflects underlying neurobiological heterogeneity in alcohol use disorder [^4][^31]. Early-onset alcoholics and specific genetic variants appear associated with enhanced serotonergic dysfunction, making them more responsive to 5-HT3 receptor antagonism [^17][^18][^4]. The low optimal doses suggest a modulatory rather than blocking mechanism at 5-HT3 receptors [^21][^4].

### Limitations and Future Directions
Several limitations affect the interpretation of ondansetron research in AUD. Many studies had modest sample sizes, particularly in subgroup analyses [^32][^23][^33]. Replication efforts have yielded mixed results, with some recent trials failing to confirm earlier positive findings [^7][^30]. The restriction to predominantly male, Caucasian populations limits generalizability [^34][^7].

Future research should focus on larger, more diverse populations with standardized genetic stratification protocols. Combination therapy studies and investigation of novel dosing strategies warrant exploration [^35][^36]. The development of validated biomarkers beyond genetic variants could further refine patient selection [^37][^19].

## Conclusions
Ondansetron represents a promising but highly selective treatment for alcohol use disorder, with robust efficacy demonstrated in genetically and phenotypically defined subgroups comprising approximately 20-35% of the AUD population. The optimal therapeutic approach requires precision medicine strategies targeting early-onset alcoholics or individuals with specific serotonergic genetic variants using ultra-low doses (0.5-0.6 mg/day total). While not appropriate for all patients with AUD, ondansetron offers significant clinical benefits for properly selected individuals and exemplifies the potential of personalized addiction medicine. The excellent safety profile and lack of abuse potential make it particularly attractive for long-term maintenance therapy in responsive patients.

## Citations:

[^1]: Selecting an appropriate alcohol pharmacotherapy: review of recent findings. https://journals.lww.com/00001504-201907000-00003

[^2]: Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol ... https://pubmed.ncbi.nlm.nih.gov/7978099/
[^3]: 5-HT(3A) receptor subunit is required for 5-HT3 antagonist-induced reductions in alcohol drinking - PubMed https://pubmed.ncbi.nlm.nih.gov/15162158/
[^4]: The Role of 5-HT3 Receptors in Drug Abuse and as a Target for ... https://pmc.ncbi.nlm.nih.gov/articles/PMC2878195/
[^5]: Ondansetron alters human alcohol intoxication - PubMed https://pubmed.ncbi.nlm.nih.gov/8879472/
[^6]: Pharmacotherapy for Alcohol Use Disorder: A Systematic Review ... https://jamanetwork.com/journals/jama/fullarticle/2811435
[^7]: A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder. https://onlinelibrary.wiley.com/doi/10.1111/acer.14932
[^8]: A pilot study of full-dose ondansetron to treat heavy-drinking men ... https://pubmed.ncbi.nlm.nih.gov/23396176/
[^9]: Ondansetron for reduction of drinking among biologically ... - PubMed https://pubmed.ncbi.nlm.nih.gov/10944641/
[^10]: Pharmacogenetic approach at the serotonin transporter gene as a ... https://pubmed.ncbi.nlm.nih.gov/21247998/
[^11]: Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking https://www.scholars.northwestern.edu/en/publications/pharmacogenetic-approach-at-the-serotonin-transporter-gene-as-a-m
[^12]: A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. https://onlinelibrary.wiley.com/doi/10.1111/j.1530-0277.2008.00835.x
[^13]: Ondansetron use in psychiatry: a fact or fiction? https://www.cambridge.org/core/product/identifier/S1092852921000493/type/journal_article
[^14]: PREDICTION OF SEROTONERGIC TREATMENT EFFICACY USING AGE OF ONSET AND TYPE A/B TYPOLOGIES OF ALCOHOLISM https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748792/
[^15]: Medication treatment of different types of alcoholism. https://psychiatryonline.org/doi/10.1176/appi.ajp.2010.08101500
[^16]: Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.284.8.963
[^17]: Ondansetron reduces the craving of biologically predisposed ... https://pubmed.ncbi.nlm.nih.gov/11919668/
[^18]: Effect of naltrexone and ondansetron on alcohol cue-induced ... https://pubmed.ncbi.nlm.nih.gov/18391135/
[^19]: Serotonin Transporter Genomic Biomarker for Quantitative Assessment of Ondansetron Treatment Response in Alcoholics https://pmc.ncbi.nlm.nih.gov/articles/PMC3314249/
[^20]: Combining ondansetron and naltrexone reduces craving ... - PubMed https://pubmed.ncbi.nlm.nih.gov/11292002/
[^21]: Page 1/27 https://assets-eu.researchsquare.com/files/rs-2156237/v1/f176de2f-5d85-4050-a18c-b40cbebf85bb.pdf?c=1669999577
[^22]: Ondansetron reduces the craving of biologically predisposed alcoholics https://scholars.uthscsa.edu/es/publications/ondansetron-reduces-the-craving-of-biologically-predisposed-alcoh
[^23]: A candidate prospective precision medicine to treat alcohol use ... https://pubmed.ncbi.nlm.nih.gov/38876929
[^24]: Press Release - Adial Pharmaceuticals https://www.adial.com/adial-pharmaceuticals-announces-positive-topline-results-from-the-ad04-103-pharmacokinetics-study-of-ad04-for-the-treatment-of-alcohol-use-disorder/
[^25]: Safety and compliance of long-term low-dose ondansetron in ... https://pubmed.ncbi.nlm.nih.gov/38521730/
[^26]: Comparative dose-response study on the infusion of norepinephrine combined with intravenous ondansetron versus placebo for preventing hypotension during spinal anesthesia for cesarean section: a randomised controlled trial https://journals.lww.com/10.1097/JS9.0000000000000920
[^27]: Aromatherapy Versus Oral Ondansetron for Antiemetic ... - PubMed https://pubmed.ncbi.nlm.nih.gov/29463461/
[^28]: Ondansetron for Reduction of Drinking Among Biologically ... https://jamanetwork.com/journals/jama/fullarticle/193013
[^29]: Oral mannitol for bowel preparation: a dose-finding phase II study https://link.springer.com/10.1007/s00228-022-03405-z
[^30]: A randomized, double-blind, placebo-controlled, pharmacogenetic ... https://pubmed.ncbi.nlm.nih.gov/36055978/
[^31]: Ondansetron reduces mood disturbance among ... - PubMed https://pubmed.ncbi.nlm.nih.gov/14634493/
[^32]: A pilot, randomized clinical trial: Left dorsolateral prefrontal cortex intermittent theta burst stimulation improves treatment outcomes in veterans with alcohol use disorder. https://onlinelibrary.wiley.com/doi/10.1111/acer.15224
[^33]: Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 ... https://pubmed.ncbi.nlm.nih.gov/25212749/
[^34]: A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder. https://onlinelibrary.wiley.com/doi/10.1111/acer.14440
[^35]: Incorporating ondansetron and baclofen in alcohol use disorder ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9869813/
[^36]: Combination of Drugs in the Treatment of Alcohol Use Disorder - MDPI https://www.mdpi.com/2076-3425/15/6/542
[^37]: Serotonin transporter genomic biomarker for quantitative ... - PubMed https://pubmed.ncbi.nlm.nih.gov/22470354/
[^38]: Breathalyser-Based eHealth Data Suggest That Self-Reporting of Abstinence Is a Poor Outcome Measure for Alcohol Use Disorder Clinical Trials. https://academic.oup.com/alcalc/article/55/3/237/5770901
[^39]: Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial https://onlinelibrary.wiley.com/doi/10.1111/acer.14018
[^40]: Effects of ondansetron in early- versus late-onset alcoholics - PubMed https://pubmed.ncbi.nlm.nih.gov/12878921/
[^41]: Ondansetron for Bipolar and Alcohol Use Disorders - ClinicalTrials.gov https://cdn.clinicaltrials.gov/large-docs/78/NCT02082678/Prot_SAP_000.pdf
[^42]: A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder https://pmc.ncbi.nlm.nih.gov/articles/PMC9901168/
[^43]: Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial https://scholars.uthscsa.edu/en/publications/ondansetron-for-reduction-of-drinking-among-biologically-predispo
[^44]: A prospective, open-label trial of ondansetron in adolescents with alcohol dependence - PubMed https://pubmed.ncbi.nlm.nih.gov/15925118/
[^45]: A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder https://utsouthwestern.elsevierpure.com/en/publications/a-randomized-double-blind-placebo-controlled-proof-of-concept-stu
[^46]: Isopropyl alcohol inhalation for the treatment of nausea in adult emergency department patients: a systematic review and meta-analysis https://emj.bmj.com/lookup/doi/10.1136/emermed-2022-212871
[^47]: The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-024-02476-6
[^48]: Digital Interventions for People With Co-Occurring Depression and Problematic Alcohol Use: A Systematic Review and Meta-Analysis https://academic.oup.com/alcalc/article/57/1/113/6136819
[^49]: Linking Big Five Personality Domains and Facets to Alcohol (Mis)Use: A Systematic Review and Meta-Analysis. https://academic.oup.com/alcalc/article/57/1/58/6248496
[^50]: Methamphetamine exposure and depression-A systematic review and meta-analysis. https://onlinelibrary.wiley.com/doi/10.1111/dar.13670
[^51]: Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. https://onlinelibrary.wiley.com/doi/10.1002/bdr2.1705
[^52]: Isopropyl alcohol inhalation for the treatment of nausea in adult ... https://pubmed.ncbi.nlm.nih.gov/37076258/
[^53]: Psychosocial and pharmacologic interventions to reduce harmful ... https://pubmed.ncbi.nlm.nih.gov/37158538/
[^54]: Incorporating ondansetron and baclofen in alcohol use disorder ... https://europepmc.org/article/pmc/pmc9869813
[^55]: Guideline No. 405: Screening and Counselling for Alcohol ... - PubMed https://pubmed.ncbi.nlm.nih.gov/32900457/
[^56]: Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse https://pmc.ncbi.nlm.nih.gov/articles/PMC4086466/
[^57]: Aromatherapy with Isopropyl Alcohol versus Intravenous Ondansetron in Management of Mild Brain Trauma Nausea and Vomiting; a Randomized Clinical Trial https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/1792
[^58]: Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders https://www.tandfonline.com/doi/full/10.1080/13543784.2018.1502269
[^59]: Rates of Discontinuation and Non-Publication of Trials for the Pharmacologic Treatment of Alcohol Use Disorder https://journals.sagepub.com/doi/10.1080/08897077.2021.2010261
[^60]: Promoting Race and Ethnic Diversity in a Hospital-Based Randomized Clinical Trial to Address Untreated Alcohol Use Disorder: Initial Lessons Learned https://journals.lww.com/10.1097/ADM.0000000000001400
[^61]: Pharmacotherapy for Alcohol Use Disorder: Enhancing Health and Treatment Outcomes https://apcz.umk.pl/QS/article/view/58999
[^62]: Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries. http://doi.wiley.com/10.1002/14651858.CD013350.pub2
[^63]: Anticraving therapy for alcohol use disorder: A clinical review. https://europepmc.org/article/med/30175522
[^64]: [PDF] Ondansetron: A Selective 5-HT3 Receptor Antagonist ... - Europe PMC https://europepmc.org/articles/pmc6741689?pdf=render
[^65]: Reductions in and relations between "craving" and drinking in a ... https://pubmed.ncbi.nlm.nih.gov/16084024/
[^66]: Serotonin3 receptor antagonism of alcohol intake: effects of drinking ... https://pubmed.ncbi.nlm.nih.gov/9590513/
[^67]: Ondansetron reduces naturalistic drinking in non-treatment seeking ... https://pmc.ncbi.nlm.nih.gov/articles/PMC4047179/
[^68]: Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2012.00023/pdf
[^69]: Alcohol consumption in Iran: A systematic review and meta-analysis of the literature. https://onlinelibrary.wiley.com/doi/10.1111/dar.13093
[^70]: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-4-1
[^71]: A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype - PubMed https://pubmed.ncbi.nlm.nih.gov/21192139/
[^72]: Effect of drugs influencing 5-HT function on ethanol drinking and ... https://pubmed.ncbi.nlm.nih.gov/1480350/
[^73]: The Use of Selective Serotonin Reuptake Inhibitors in Treating ... https://www.psychiatrist.com/pdf/the-use-of-selective-serotonin-reuptake-inhibitors-in-treating-alcoholic-subtypes-pdf/
[^74]: A randomized, double-blind, placebo-controlled trial of ondansetron ... https://pmc.ncbi.nlm.nih.gov/articles/PMC8595865/
[^75]: A Double-blind, Randomized Trial of Sertraline for Alcohol ... https://pmc.ncbi.nlm.nih.gov/articles/PMC3130300/
[^76]: Message for DARE database users https://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008106086
[^77]: Bibliometric Analysis of Clinical Trials on the Effect of Sugar Alcohol Consumption on Oral Health: Trends, Insights, and Future Directions (1967-2024) https://www.cureus.com/articles/254046-bibliometric-analysis-of-clinical-trials-on-the-effect-of-sugar-alcohol-consumption-on-oral-health-trends-insights-and-future-directions-1967-2024
[^78]: Barbiturates Versus Benzodiazepine for the Treatment of Severe Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials https://www.researchsquare.com/article/rs-1121796/v1
[^79]: Isopropyl alcohol inhalation versus 5-HT3 antagonists for treatment of nausea: a meta-analysis of randomised controlled trials https://link.springer.com/10.1007/s00228-023-03560-x
[^80]: The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials https://www.mdpi.com/1648-9144/61/2/278
[^81]: Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing non-laparoscopic surgery: A systematic review and meta-analysis of randomised controlled trials https://journals.lww.com/10.4103/ija.ija_1017_24
[^82]: Text messages as a tool to improve cardiovascular disease risk factors control: a systematic review and meta-analysis of randomized clinical trials https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21818-0
[^83]: Determination of genotype combinations that can predict ... - PubMed https://pubmed.ncbi.nlm.nih.gov/23897038/
[^84]: Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study. https://onlinelibrary.wiley.com/doi/10.1111/acer.12410
[^85]: Comparative Study between Ondansetron, Isopropyl Alcohol Inhalation and Super Hydration in Treatment of Postoperative Emesis after Laparoscopic Appendectomy https://www.semanticscholar.org/paper/8f8666c37505ad025bc21cd9f3be0345d3ca6a72
[^86]: Effect of Full-Dose Ondansetron on Tobacco Use among Male Alcohol- Dependent Outpatients - A Preliminary Study https://www.omicsonline.org/effect-of-full-dose-ondansetron-on-tobacco-use-among-male-alcohol-dependent-outpatients-a-preliminary-study-2155-6105.1000150.php?aid=14697
[^87]: QOL-08. PHASE II RANDOMIZED STUDY TO EVALUATE EFFICACY AND SATISFACTION OF ROLAPITANT PLUS ONDANSETRON VS. ONDANSETRON MONOTHERAPY IN PREVENTING NAUSEA/VOMITING FOR GLIOMAS RECEIVING RADIATION/TEMOZOLOMIDE https://academic.oup.com/neuro-oncology/article/24/Supplement_7/vii242/6826658
[^88]: Ondansetron reduces naturalistic drinking in nontreatment ... - PubMed https://pubmed.ncbi.nlm.nih.gov/24773166/
[^89]: A within-group design of nontreatment seeking 5-HTTLPR ... - PubMed https://pubmed.ncbi.nlm.nih.gov/19032576/
[^90]: Medications acting on the serotonergic system for the treatment of ... https://pubmed.ncbi.nlm.nih.gov/20482508/
[^91]: Current and promising pharmacotherapies, and novel ... - PubMed https://pubmed.ncbi.nlm.nih.gov/21524263/
[^92]: A randomized, double-blind, placebo-controlled proof-of-concept ... https://pubmed.ncbi.nlm.nih.gov/33402258/
[^93]: A randomized, double-blind, placebo-controlled proof-of-concept ... https://www.sciencedirect.com/science/article/abs/pii/S0924977X20309871
[^94]: Serotonin Transporter Genomic Biomarker for ... - Frontiers https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2012.00023/full
[^95]: Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. https://onlinelibrary.wiley.com/doi/10.1097/01.ALC.0000075547.77464.76
[^96]: Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. https://onlinelibrary.wiley.com/doi/10.1111/j.1530-0277.2008.00717.x
[^97]: Combining ondansetron and naltrexone effectively treats ... - PubMed https://pubmed.ncbi.nlm.nih.gov/10832917/
[^98]: Single intravenous dose ondansetron induces QT prolongation in adult emergency department patients: a prospective observational study https://intjem.biomedcentral.com/articles/10.1186/s12245-024-00621-5
[^99]: Association and dose-response relationship between exposure to alcohol advertising media and current drinking: a nationwide cross-sectional study of Japanese adolescents https://www.jstage.jst.go.jp/article/ehpm/28/0/28_23-00127/_article
[^100]: Advances in Medications and Tailoring Treatment for Alcohol Use ... https://pdfs.semanticscholar.org/1a96/300f0422cd2ebe9588fbaa4041c3d901f354.pdf
[^101]: The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. https://linkinghub.elsevier.com/retrieve/pii/S0376871620301587
[^102]: Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials https://academic.oup.com/alcalc/article/58/5/478/7234661
[^103]: Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series. https://www.psychiatrist.com/jcp/decreased-alcohol-use-disorder-symptoms-with-semaglutide-for-weight-loss-a-case-series/
[^104]: N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. https://academic.oup.com/alcalc/article/58/5/553/7225905
[^105]: The use of N-acetylcysteine in the prevention of hangover: a randomized trial – DOAJ https://doaj.org/article/0d6dd1fafb0e457682a6c0936f963267
[^106]: Low-dose ondansetron: A candidate prospective precision medicine ... https://www.sciencedirect.com/science/article/pii/S0953620524002401
[^107]: Effect of alcohol interventions on suicidal ideation and behaviour: A systematic review and meta-analysis. https://linkinghub.elsevier.com/retrieve/pii/S037687162100380X
[^108]: Association of E-cigarettes with adolescent alcohol use and binge drinking-drunkenness: A systematic review and meta-analysis https://www.tandfonline.com/doi/full/10.1080/00952990.2020.1771723
[^109]: A randomized, double-blind, placebo-controlled trial of ondansetron ... https://pubmed.ncbi.nlm.nih.gov/34600264/
[^110]: Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials https://www.bmj.com/lookup/doi/10.1136/bmj.328.7441.680
[^111]: An Overview of Glycine Transporter Subtype 1 Inhibitors Under Preclinical and Clinical Evaluation for the Treatment of Alcohol Abuse https://www.eurekaselect.com/200513/article
[^112]: Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder. https://onlinelibrary.wiley.com/doi/10.1111/add.16610
[^113]: (PDF) Randomized Controlled Trial of Ondansetron vs ... https://pdfs.semanticscholar.org/4cb9/40424a12a1896662e9c9664eb7154c8d0193.pdf
[^114]: Ondansetron Completed Phase 2 Trials for Alcohol ... - DrugBank https://go.drugbank.com/drugs/DB00904/clinical_trials?conditions=DBCOND0071586&phase=2&purpose=treatment&status=completed
[^115]: [PDF] A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose ... https://scispace.com/pdf/a-prospective-precision-medicine-phase-3-clinical-trial-of-1owo1xj8.pdf
[^116]: Disparities in alcohol use and heavy episodic drinking among bisexual people: A systematic review, meta-analysis, and meta-regression. https://linkinghub.elsevier.com/retrieve/pii/S0376871622001703
[^117]: Brief interventions for cannabis use in emerging adults: A systematic review, meta-analysis, and evidence map. https://linkinghub.elsevier.com/retrieve/pii/S0376871619303424
[^118]: Anticraving Medications for Relapse Prevention: A Possible New ... https://www.medrxiv.org/lookup/external-ref?access_num=10.1176%2Fappi.ajp.162.8.1423&link_type=DOI
[^119]: Quetiapine in relapse prevention in alcoholics suffering from craving ... https://www.medrxiv.org/lookup/external-ref?access_num=10.1016%2Fj.eurpsy.2006.04.007&link_type=DOI
[^120]: Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder https://www.tandfonline.com/doi/full/10.1080/14728214.2024.2342951
[^121]: No Wrong Doors: Findings from a Critical Review of Behavioral Randomized Clinical Trials for Individuals with Co‐Occurring Alcohol/Drug Problems and Posttraumatic Stress Disorder https://onlinelibrary.wiley.com/doi/10.1111/acer.13325
[^122]: A randomized, double‐blind, placebo‐controlled, pharmacogenetic ... https://onlinelibrary.wiley.com/doi/abs/10.1111/acer.14932
[^123]: A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder https://linkinghub.elsevier.com/retrieve/pii/S0924977X20309871
[^124]: Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings. https://linkinghub.elsevier.com/retrieve/pii/S0741832914200887
[^125]: A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil. https://linkinghub.elsevier.com/retrieve/pii/S030646031200408X
[^126]: Pharmacotherapy, pharmacogenomics, and the future of alcohol ... https://pubmed.ncbi.nlm.nih.gov/15552634/
[^127]: A Within‐Group Design of Nontreatment Seeking 5‐HTTLPR ... https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1530-0277.2008.00835.x
[^128]: s02 serotonin system in alcoholism: individual differences and ... https://academic.oup.com/alcalc/article/48/suppl_1/i3/210519
[^129]: Ondansetron effective in early-onset alcoholism http://link.springer.com/10.2165/00128413-200012530-00028
[^130]: Ondansetron to treat early-onset alcoholism? https://linkinghub.elsevier.com/retrieve/pii/S0140673605736461
[^131]: Ondansetron reduces drinking in early-onset alcoholism, researchers find https://academic.oup.com/ajhp/article/57/19/1742/5156914
[^132]: Ondansetron With and Without Naltrexone As a Treatment of Biologic Alcoholism: Concepts and Updated Findings http://journals.lww.com/00132576-200209000-00001
[^133]: FORMULATION AND EVALUATION OF ORALLY DISINTEGRATING TABLETS OF ONDANSETRON HYDROCHLORIDE BY SUBLIMATION TECHNIQUE https://www.semanticscholar.org/paper/bb481acc4e9d558190df4d6641d0d8b2d84fa556
[^134]: The role of anxiety in predicting drinking behaviour - PubMed https://pubmed.ncbi.nlm.nih.gov/12814905/
[^135]: Ondansetron to treat early-onset alcoholism? - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)73646-1/fulltext
[^136]: Effects of Ondansetron in Early‐ Versus Late‐Onset Alcoholics https://onlinelibrary.wiley.com/doi/abs/10.1097/01.ALC.0000075547.77464.76
[^137]: [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. https://www.semanticscholar.org/paper/25e8e5d4a61f6f347cca46c94c02d754bec39c76
[^138]: [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. https://www.semanticscholar.org/paper/3fc68e418708eea7095b2710c3d430e1ae3d064c
[^139]: Management of alcohol dependence in patients with liver disease https://pubmed.ncbi.nlm.nih.gov/23456576/
